SOUTH SAN FRANCISCO, Calif., April 5, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced the appointment of Tamar Howson and its current CEO, Dr. Peter J. Langecker, to its Board of Directors.
